Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Scientists hunt for better breast cancer blood tests

NCT ID NCT05054010

Knowledge-focused Sponsor: Tethis S.p.A. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is testing commercially available antibodies to see if they can identify breast cancer markers in blood samples. Researchers will collect blood from 84 people, including breast cancer patients and healthy volunteers. The goal is to improve detection of circulating tumor cells, which could help with diagnosis or monitoring in the future.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could lead to better blood tests for detecting breast cancer cells, potentially improving early diagnosis or monitoring.
What could go wrong
This is an early exploratory study with only 84 participants, so results may not apply broadly. The antibodies are for research use only, not yet for clinical diagnosis.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

84 people

The number who actually took part.

Started

Oct 2021

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Participants will be selected from among the people who visit the Breast Surgery department

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Participant is willing and able to give and sign a written informed consent for participation in the study. * Female aged 18 years or above. * Diagnosed with early breast cancer (stage I and II) or metastatic breast cancer. * Healthy participants who visit the site for reason other than cancer diagnosis (including breast cancer). Exclusion Criteria: * History of other malignancies other than breast cancer (for healthy participants includes also breast cancer). * Undergone surgery or treatment for breast cancer before enrollment (only for early breast cancer). * Presence of known severe coagulation or haematological disorder * Known Pregnancy * Absence of written signed informed consent for participation in the study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Breast neoplasms are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

breast cancer breast carcinoma breast neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Breast neoplasms

Contacts and locations

Locations

  • Ospedale San Raffaele

    Milan, 20132, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.